SCHEMBL4737869

SCHEMBL4737869

CC(C)OCCCn1c(Cc2ccccc2)nc(O)cc1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.45
KDM4E B2RXH2 4/20 0.45
GAA P10253 4/20 0.45
MAPT P10636 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
HDAC1 Q13547 1/20 0.43
LMNA P02545 2/20 0.41
POLB P06746 1/20 0.41
TSHR P16473 1/20 0.41
GLA P06280 3/20 0.40
HPGD P15428 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
TDP1 Q9NUW8 2/20 0.40
TP53 P04637 1/20 0.40
BCHE P06276 1/20 0.38
ACHE P22303 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
ALOX12 P18054 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4737871 0.84 GSK3B (0.42) ALDH1A1KDM4EMAPTSMN1; SMN2LMNA
SCHEMBL4741835 0.76 LMNA (0.51) ALDH1A1KDM4EMAPTSMN1; SMN2LMNA
SCHEMBL4989787 0.74 EGLN1 (0.44) ALDH1A1KDM4EGAAMAPTSMN1; SMN2
SCHEMBL4738614 0.71 GSK3B (0.46) ALDH1A1KDM4EMAPTSMN1; SMN2LMNA
SCHEMBL4739999 0.70 LMNA (0.45) ALDH1A1KDM4EGAAMAPTSMN1; SMN2
SCHEMBL4739122 0.66 KMT2A (0.47) ALDH1A1KDM4EGAAMAPTSMN1; SMN2
SCHEMBL11321373 0.66 GAA (0.42) ALDH1A1KDM4EGAAMAPTSMN1; SMN2
SCHEMBL4739125 0.65 GSK3B (0.51) ALDH1A1KDM4EMAPTSMN1; SMN2LMNA
SCHEMBL3521617 0.64 ALDH1A1 (0.51) ALDH1A1KDM4EMAPTSMN1; SMN2LMNA
SCHEMBL31424903 0.62 SMN1; SMN2 (0.47) ALDH1A1KDM4EGAAMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008089051-A1 N-SUBSTITUTED GLYCINE DERIVATIVES: PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-07-24 WO disclosed
US-20080171756-A1 N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2008-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171756-A1 N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors HIF1AN, EGLN2, EGLN3 ALDH1A1 513/4885KDM4E 746/4885GAA 172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.